This would centralise decision-making in a single and all-powerful statutory HTA body with powers over medicines, vaccines, blood products, diagnostics, medical devices and other technologies.
The proposed centralisation of power needs careful consideration by other sectors
February 8, 2024 Latest NewsBioPharmaComment![](https://e76bb9fd1f54a7a912eb-40f6ec802f763655ee14c32dfe77820e.ssl.cf4.rackcdn.com/da217971d1173ed7d132efe003b0cb7e.png)
Latest Video
New Stories
-
The 'Week in Review' Podcast - 26 July
July 26, 2024 - - Podcast -
'We approached stakeholders that were highly engaged with the HTA review process'
July 26, 2024 - - Latest News -
Preaching transparency and not practising it is the worst possible look
July 26, 2024 - - Latest News -
Cartherics announces new licensing agreement for innovative cardiac cell therapy
July 25, 2024 - - Latest News -
New large study shows vaccination halves the risk of patients suffering Long-COVID
July 25, 2024 - - Latest News -
These layered levels of privilege are not making decision-making or the system better
July 25, 2024 - - Latest News -
Telix completes significant raise that could be used for acquisitions
July 25, 2024 - - Latest News